




RealRate

PHARMACEUTICAL 2018

VYNE Therapeutics Inc. Rank 120 of 342





RealRate

PHARMACEUTICAL 2018

VYNE Therapeutics Inc. Rank 120 of 342



The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 92% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 149%, being 104% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	63,861
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,817
Liabilities, Non-Current	22
Other Assets	2,978
Other Compr. Net Income	-25
Other Expenses	0
Other Liabilities	6,735
Other Net Income	5,099
Other Revenues	0
Property and Equipment	28
Research and Development	29,007
Selling, General and Administrative Expense	5,168

Output Variable	Value in 1000 USD
Assets	66,867
Liabilities	14,574
Expenses	34,175
Revenues	0
Stockholders Equity	52,293
Net Income	-29,076
Comprehensive Net Income	-29,088
Economic Capital Ratio	149%